drug development Archives

Illustration of a bullish investment landscape showing AI-powered ecommerce, healthcare innovation, cybersecurity and market growth. Robots manage online-shopping fulfillment around an ecommerce screen, clinicians and researchers work in a modern medical setting, and professionals point toward rising stock charts and upward arrows, with the phrases “AI Commerce,” “Healthcare” and “Stay Engaged.”

A Resilient Economy, AI Commerce & Healthcare Catalysts Give Many More Than One Reason to Stay Engaged -( $AMWL $AMZN $APPL $CRWD $GOOG $OKTA $PANW $PYPL $SER $SHOP $SMWB $XYZ $ZS )

by John F. Heerdink, Jr. September 14, 2026 303Views 0Likes

Many entered the week bracing for a Federal Reserve rate hike, yet the more constructive takeaway may be that policy makers still have room to choose patience. That possibility, alongside fresh evidence of AI-led ecommerce change, government-scale digital-health demand and advancing biotech milestones,…

Investor infographic illustrating Eli Lilly and Company (NYSE: LLY) investing up to $2.875 billion to acquire Merida Biosciences, linking Lilly’s headquarters and cash investment to Merida’s antibody-engineering candidates, precision immunology research, and projected future revenue growth.

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. September 1, 2026 219Views 0Likes

Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…

Eupraxia Pharmaceuticals: The Small‑Cap Biotech Quietly Seeking To Build a Billion‑Dollar Plus EoE Franchise -( $EPRX $IBB $XBI )

by Vista Partners LLC December 12, 2025 784Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX, $6.40, +1.59% today and +85.51% over the last year) is emerging as a standout small‑cap biotech, transforming a once‑niche GI indication and routine endoscopy visits into a compelling, scalable growth platform, underpinned by a mid‑teens price target from…

The Year of the Bispecific: Biotech’s Double-Edged Breakout -( $ARKG $IBB $XBI $RHBBY $AMGN $JNJ )

by Vista Partners LLC December 10, 2025 477Views 0Likes

If 2024 crowned weight-loss drugs the belle of the healthcare ball, 2025 belongs to the bispecific antibody. What began as a niche in immuno-oncology has evolved into biotech’s most competitive—and potentially lucrative—battleground, drawing fresh capital, dealmaking, and analyst optimism that borders on…

“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )

by John F. Heerdink, Jr. June 16, 2025 518Views 0Likes

In the bustling digital amphitheater of Tribe Public’s latest CEO Presentation, the question of the hour was as sharp as it was timely: “Is the beaten down biotech sector the smartest bet in today’s volatile market?” With a flourish of slides and…

Tag: drug development

A Resilient Economy, AI Commerce & Healthcare Catalysts Give Many More Than One Reason to Stay Engaged -( $AMWL $AMZN $APPL $CRWD $GOOG $OKTA $PANW $PYPL $SER $SHOP $SMWB $XYZ $ZS )

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

Eupraxia Pharmaceuticals: The Small‑Cap Biotech Quietly Seeking To Build a Billion‑Dollar Plus EoE Franchise -( $EPRX $IBB $XBI )

The Year of the Bispecific: Biotech’s Double-Edged Breakout -( $ARKG $IBB $XBI $RHBBY $AMGN $JNJ )

“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )

Your Guide To Staying Informed In The Markets